reports
SteadyMed Provides Corporate Update and Reports Second Quarter 2018 Fi...
SteadyMed Provides Corporate Update and Reports Second Quarter 2018 Financial Results SAN RAMON, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today provided a corporate update and announced its financial results for the second quarter ended June 30, 2018. Summary Corporate Update: On July 31, 2018, SteadyMed announced that its shareholders voted to approve the previously announced acquisition of...
SteadyMed Shareholders Approve Proposed Acquisition by United Therapeu...
SteadyMed Shareholders Approve Proposed Acquisition by United Therapeutics SAN RAMON, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that SteadyMed shareholders voted to approve the previously announced acquisition of the company by United Therapeutics Corporation (NASDAQ: UTHR) at an extraordinary general meeting of shareholders held on July 30, 2018. SteadyMed shareholders also app...
HSR Act Waiting Period Terminated for United Therapeutics’ Acquisiti...
HSR Act Waiting Period Terminated for United Therapeutics’ Acquisition of SteadyMed Ltd. SILVER SPRING, Md. and SAN RAMON, Calif., July 20, 2018 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (NASDAQ:UTHR) and SteadyMed Ltd. (NASDAQ:STDY) announced today the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) relating to United Therapeutics’ previously announced acquisition of SteadyMed. As previously announced on April 30, 2018, United Therapeutics and SteadyMed entered into a definitive merger agreement under which Unite...
2 directors sold
Two Directors at Steadymed Ltd sold 56,567 shares at 4.500USD. The significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
The Law Offices of Vincent Wong Notifies Investors of an Investigation...
NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong are investigating the Board of Directors of SteadyMed Ltd. (“SteadyMed” or the “Company”) (NASDAQGM: STDY) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to United Therapeutics Corporation. Under the terms of the deal, SteadyMed stockholders will receive $4.46 per share in cash, with an additional $2.63 per share in cash upon achievement of a certain milestone related to SteadyMed’s Trevyent drug-device com...
INVESTOR ALERT: Brower Piven Commences an Investigation into the Propo...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of SteadyMed Ltd. (Nasdaq: STDY) (“SteadyMed” or the “Company”) relating to the proposed buyout of SteadyMed by United Therapeutics Corporation. Under the terms of the agreement, SteadyMed shareholders are anticipated to receive $4.46 per share in cash, with an additional $2.63 per sh...
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investig...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased SteadyMed Ltd. (“SteadyMed” or the “Company”) (NASDAQGM: STDY) stock prior to April 30, 2018. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of SteadyMed to United Therapeutics Corporation (NASDAQGS: UTHR). Under the terms of the transaction, SteadyMed shareholders will receive $4.46 per share in cash, with an ad...
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Pr...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of SteadyMed Ltd. (Nasdaq: STDY) (“SteadyMed” or the “Company”) relating to the proposed buyout of SteadyMed by United Therapeutics Corporation. Under the terms of the agreement, SteadyMed shareholders are anticipated to receive $4.46 per share in cash, with an additional $2.63 per sh...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Inve...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased SteadyMed Ltd. (“SteadyMed” or the “Company”) (NASDAQGM: STDY) stock prior to April 30, 2018. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of SteadyMed to United Therapeutics Corporation (NASDAQGS: UTHR). Under the terms of the transaction, SteadyMed shareholders will receive $4.46 per share in cash, with an ad...
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investig...
NEW YORK--(BUSINESS WIRE)-- Levi & Korsinsky announces it has commenced an investigation of SteadyMed Ltd. (“SteadyMed” or the “Company”) (NASDAQ:STDY) concerning possible violations of federal securities laws. On August 31, 2017, SteadyMed revealed that it received a Refusal to File letter from the U.S. Food and Drug Administration ("FDA") regarding it New Drug Application ("NDA") for its product candidate Treyvent. Based on a preliminary review of the NDA, which was submitted in June 2017, the FDA determined that the applic...
STEADYMED LTD. INVESTOR ALERT: Girard Gibbs Investigates Potential Sec...
OAKLAND, Calif.--(BUSINESS WIRE)-- Girard Gibbs LLP is investigating claims on behalf of investors of SteadyMed Ltd. (NASDAQ: STDY) regarding possible violations of federal securities laws following the FDA’s refusal to review the company’s new drug application for Trevyent. To speak privately with an attorney regarding this class action lawsuit investigation, click here. On August 31, 2017, SteadyMed announced that it had received a Refusal to File letter from the FDA regarding the company’s New Drug Applicat...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Inves...
NEW YORK--(BUSINESS WIRE)-- Levi & Korsinsky announces it has commenced an investigation of SteadyMed Ltd. (“SteadyMed” or the “Company”) (NASDAQ: STDY) concerning possible violations of federal securities laws. On August 31, 2017, SteadyMed revealed that it received a Refusal to File letter from the U.S. Food and Drug Administration ("FDA") regarding it New Drug Application ("NDA") for its product candidate Treyvent. Based on a preliminary review of the NDA, which was submitted in June 2017, the FDA determined that the appli...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.